alemtuzumab
alemtuzumab: 10 clinical trials tracked.
alemtuzumab evidence translation
What we can confirm
10 tracked trials
What it means
What to watch
Prepared research question
What is verified about alemtuzumab, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 4 study sponsors
Clinical Trials (10)
Haploidentical Donor Hematopoietic Cell Transplant for Sickle Cell Disease
Primary endpoint: GVHD-free and rejection free survival (GRFS)
Open-label, Single-Center, Phase 1 Study to Estimate the Minimum Effective Dose (MED) of 131I-apamistamab for Non-myeloablative Conditioning in Patients With Severe Sickle Cell Disease
Primary endpoint: Graft failure rate
Sickle Cell Disease Transplant Using a Nonmyeloablative Approach: Adding Daratumumab for Patients With Anti-donor Red Cell AntibodY
Primary endpoint: To determine the event-free survival of children and adolescents with SCD undergoing nonmyeloablative HCT who received 4 doses of pre-HCT daratumumab for donor-directed red blood cell antibodies.
Pregnancy Outcomes in Women Exposed to Diroximel Fumarate
Primary endpoint: Number of Major Congenital Malformations (MCMs)
Donor-derived Mesenchymal Stromal Cells, Alemtuzumab, Co-stimulation Blockade and Sirolimus for Tolerance Induction in Adult Kidney Allograft Recipients (ITN062ST)
Primary endpoint: Proportion of Participants who Achieve Operational Tolerance
Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
Primary endpoint: Acute GVHD
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease
Primary endpoint: Percentage of Participants Who Have Not Rejected Their Stem Cell Graft and Who Are Without Severe Graft-versus-host Disease Following Stem Cell Transplant
High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease
Primary endpoint: To determine engraftment rates with the use of high cell doses, without increasing the risk of GvHD by using post-transplant cyclophosphamide and sirolimus in conjunction with a busulfan- based conditioning regimen. We will compare the incidence...
International LEMTRADA Pregnancy Exposure Cohort in Multiple Sclerosis
Primary endpoint: Spontaneous abortions (≤20 weeks gestation)
Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia
Primary endpoint: Patients With Donor Type Hemoglobin